MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times (FT) reported on Monday, citing three people familiar with the matter. MoonLake's ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Merck recently made a nonbinding offer to acquire Swiss biotech firm MoonLake for over $3 billion, seeking to boost its drug ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck is in a tight spot, balancing blockbuster Keytruda’s looming 2028 patent cliff and rough seas in China’s market.

This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term ...

Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

Merck advises against changing Gardasil's approved dosing regimen despite studies suggesting single-dose efficacy. Read more ...